Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas

Diagnostic Cytopathology

Volumn 28, Issue 3, 2003, Pages 142-146

  Nizzoli, Rita ^a,c   Bozzetti, Cecilia ^a   Crafa, Pellegrino ^b   Naldi, Nadia ^a   Guazzi, Annamaria ^a   Di Blasio, Beatrice ^a   Camisa, Roberta ^a   Cascinu, Stefano ^a  

^a Ospedale di Parma   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Breast cancer; Fine needle aspiration; FISH; HER 2 neu; Immunocytochemistry

Indexed keywords

NEU DIFFERENTIATION FACTOR;

ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC DAMAGE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; ONCOGENE NEU; PRIORITY JOURNAL; RELIABILITY; SCORING SYSTEM;

ADENOCARCINOMA; BIOPSY, NEEDLE; BREAST NEOPLASMS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER;

EID: 0037336033     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.10257     Document Type: Article

References (19)

1. Ravdin P. The use of HER2 testing in the management of breast cancer. Semin Oncol 2000;27:33-42.
2. Hung MC, Lau YK. Basic science of HER-2/neu: a review. Semin Oncol 1999;26:51-59.
3. Franzèn F, Zajicek J. Aspiration biopsy in diagnosis of palpable lesions of the breast: critical review of 3479 consecutive biopsies. Acta Radiol 1968;7:241-262.
4. Nizzoli R, Bozzetti C, Naldi N, Guazzi A, Gabrielli M, Michiara M, et al. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Cancer 2000;90:61-66.
5. Makris A, Allred DC, Powles TJ, Dowsett M, Fernando IN, Trott PA, et al. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat 1997;44:65-74.
6. Bozzetti C, Nizzoli R, Naldi N, Manotti L, Savoldi L, Camisa R et al. Fine-needle aspiration technique for the concurrent immunocytochemical evaluation of multiple biologic parameters in primary breast carcinoma. Breast Cancer Res Treat 1994;32:221-228.
7. Sauter G, Feichter G, Torhorst J, Moch H, Novotna H, Wagner U, et al. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol 1996;40:164-173.
8. McManus DT, Patterson AH, Maxwell P, Humphreys MW, Anderson NH. Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates. Mol Pathol 1999;52:75-77.
9. Mezzelani A, Alasio L, Bartoli C, Bonora MG, Pierotti MA, Rilke F, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 1999;80:519-525.
10. Klijanienko J, Couturier J, Galut M, El-Naggar AK, Maciorowski Z, Padoy E, et al. Detection and quantitation by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer 1999:87:312-318.
11. Makris A, Powles TJ, Dowsett M, Osbome CK, Trott PA, Fernando IN, et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 1997;3:593-600.
12. Jorda M, Ganjei P, Nadji M. Retrospective c-erbB-2 immunostaining in aspiration cytology of breast cancer. Diagn Cytopathol 1994;11:262-265.
13. Bozzetti C, Nizzoli R, Guazzi A, Flora M, Bassano C, Crafa P, Naldi N, Cascinu S. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Ann Oncol 2002;13:1398-1403.
14. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
15. Corkill ME, Katz R. Immunocytochemical staining of c-erbB-2 oncogene in fine-needle aspirates of breast carcinoma: a comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 1994;11:250-254.
16. Troncone G, Panico L. Vetrani A, de Divitiis B, Zeppa P, Fulciniti F, et al. c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol 1996;14:135-139.
17. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
18. Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 1987;2:69-72.
19. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.